AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01147523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone/Vitamin E
Description: Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
Study NCT05247775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Profilometry
Description: Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
Study NCT04861909 — intervention group
Intervention type: DEVICE
Intervention: AT LISA tri 839MP
Description: Non interventional study
Study NCT01981330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMSC+hyaluronan gel
Description: aMSC+ hyaluronan gel is injected into the patients vocal fold
Study NCT03663101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
Study NCT03663101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
Study NCT01358045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Application on the lesion 2 times a day 8 weeks.
Study NCT01358045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac + Calcitriol
Description: Application on the lesion 2 times a day, both ointments, 8 weeks.
Study NCT01358045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Application on the lesion, 2 times a day, 8 weeks.
Study NCT04263337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study NCT01010373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101
Description: 3 mg/m2 AS101 will be given intravenously (IV) three times per week.
Study NCT03751696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Coaching
Description: 4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
Study NCT03751696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS self-help tips
Description: 4 mental well-being tips through sms within 8 weeks
Study NCT01999868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab.
Study NCT03663101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
Study NCT03663101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
Study NCT01999868 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab.
Study NCT01999868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection
Study NCT01999868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UST Placebo
Description: The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
Study NCT01999868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABA Placebo
Description: The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
Study NCT03276039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasma pentraxin-3
Description: Plasma pentraxin-3 was measured using ELISA
Study NCT00644228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00644228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT00644228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT00644228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00644228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00644228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT04263337 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [18F] Flortaucipir
Description: Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study NCT00644228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00662636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT00662636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT00662636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study (cohort II only)
Study NCT00662636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study (cohort II only)
Study NCT04282980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: Oral kinase inhibitor
Study NCT00457301 — intervention group
Intervention type: BEHAVIORAL
Intervention: HUI score card
Description: Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
Study NCT04530526 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regenerative Peripheral Nerve Interface
Description: The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
Study NCT01790893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Study NCT04822324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spencer Muscle energy technique with conventional Physiotherapy
Description: shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises
Study NCT04822324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique
Description: Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess.
Study NCT00364845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
Study NCT00364845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prefilled syringe placebo, to match active arm
Study NCT00034541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 i.v. over 120 minutes
Study NCT00034541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/m2, infusion
Study NCT00034541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 30-minute AUC = 6, infusion.
Study NCT04734938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Huel Powder
Description: Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
Study NCT03697473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic hamstring exercise
Description: The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
Study NCT03697473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension exercise
Description: The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
Study NCT03999177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinect-TOLF Training System
Description: This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
Study NCT00113503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine weight-based dose
Study NCT00113503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine individualised dose
Study NCT03947801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greek Yogurt
Description: Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
Study NCT03947801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isoenergetic carbohydrate
Description: Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
Study NCT04345991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transfusion of COVID-19 convalescent plasma
Description: Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
Study NCT01268969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KARYDAKIS GROUP
Description: The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
Study NCT01268969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lamberg flap technique
Description: The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 180 mg, once daily, until disease progression
Study NCT00255112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: family based cognitive behavior therapy
Description: newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
Study NCT03925857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
Study NCT01262911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2379
Description: SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
Study NCT01262911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study NCT02012283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food consumption
Description: Cooked vegetables with spices or without spices
Study NCT02012283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food consumption
Description: Cooked vegetables with spices or without spices
Study NCT05108285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)
Description: OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 320 mg, once daily, until disease progression
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 600 mg, once daily, until disease progression
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, until disease progression
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
Study NCT02369016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY 80-6946)
Description: 60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Given on Day -1~Melphalan is administered according to the current SOP.
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: 200 mg/m2 IB BID given on Days -5, -4, -3, -2
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP-16
Description: 200 mg/m2 IV BID given on Days -5, -4, -3, -2
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCNU
Description: BCNU 300 mg/m2 IV given on Day -6
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituxan
Description: 375 mg/m2 IB given on Days -6, +14, +21, +28
Study NCT01702961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stem Cells
Description: Stem cells given on Day 0
Study NCT04431180 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
Study NCT04431180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
Study NCT03277664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone.
Study NCT00207103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanab
Description: Tablets, Oral, 1000 mg, once daily, until disease progression
Study NCT02610400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RACD
Description: Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop
Study NCT02610400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RAVC
Description: Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.